Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06952699 | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | PHASE2 | RECRUITING | 88 | — | — | May 6, 2025 | Aug 20, 2026 | May 27, 2026 | 52 | United States, China +5 |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.
| Arm | Type | Description |
|---|---|---|
| TAK-360 | EXPERIMENTAL | Participants will receive TAK-360 tablets, orally, for 4 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive TAK-360 matching-placebo tablets, orally, for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| TAK-360 | DRUG | TAK-360 tablet. |
| Placebo | OTHER | TAK-360 matching placebo tablet. |
Key Inclusion Criteria: 1. The participant weighs greater than equal or to (≥)40 kilograms (kg) and has a body mass index (BMI) between 16 and 38 kilograms per meter square (kg/m\^2) \[inclusive\]. 2. The participant has a documented, current diagnosis of NT2. Key Exclusion Criteria: 1. The parti...